International Flavors (IFF) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended June 2026, International Flavors (IFF) reported revenue of $1.95 billion, down 29.3% over the same period last year. EPS came in at $0.82, compared to $1.15 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $2.68 billion, representing a surprise of -27.16%. The company delivered an EPS surprise of -28.07%, with the consensus EPS estimate being $1.14.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

• Net Sales- Health & Biosciences: $601 million compared to the $601.59 million average estimate based on four analysts. The reported number represents a change of +4.2% year over year.
• Net Sales- Scent: $665 million versus the four-analyst average estimate of $622.95 million. The reported number represents a year-over-year change of +10.3%.
• Net Sales- Taste: $688 million versus $648.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9% change.
• Adjusted Operating EBITDA- Health & Biosciences: $150 million versus $158.41 million estimated by four analysts on average.
• Adjusted Operating EBITDA- Taste: $124 million compared to the $131.72 million average estimate based on four analysts.
• Adjusted Operating EBITDA- Scent: $134 million versus the four-analyst average estimate of $128.67 million.

View all Key Company Metrics for International Flavors here>>>

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research